

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Oxycodone extended-release capsules (Xtampza ER)

#### Notes:

- ^ Adequate trial is defined as a minimum of a 2 week treatment duration with titration as needed
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- † Intolerance occurring after adjusting dose and interval AND intolerance expected to improve with ER and capsule formulation

**Initiation (new start) criteria:** Non-formulary oxycodone extended-release capsules (Xtampza ER) will be covered on the prescription drug benefit for 3 months when the following criteria are met:

- Patient has failed an adequate trial<sup>^</sup> of or has an allergy or intolerance or contraindication\* to hydrocodone/acetaminophen, morphine immediate-release (IR), hydromorphone IR, morphine extended-release (ER) and fentanyl transdermal -AND-
- Patient has documented clinically significant pain relief with trial of, but intolerance to oxycodone (IR) and oxycodone extended-release tablets<sup>†</sup>
- Prescriber is an Oncologist, Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program or a Pain Management Specialist
- Patient has had an appointment with prescriber within prior 3 months and pain management was discussed.

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary oxycodone extended-release capsules (Xtampza ER) will be covered on the prescription drug benefit for 28 days when the following criteria are met:

- Since new enrollment in Kaiser Permanente, patient has upcoming referral or appointment with Oncologist, Hospice/Palliative Care clinician or Pain Management Specialist for pain management (may be covered on drug benefit for 28 days).

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Oxycodone extended-release capsules (Xtampza ER)

**For additional prescriptions (beyond 28 days), new members entering Kaiser Permanente already taking the medication:** Non-formulary oxycodone extended-release (Xtampza ER) will be covered on the prescription drug benefit for 84 days when the following criteria are met:

- Patient has failed an adequate trial<sup>^</sup> of or has an allergy or intolerance or contraindication\* to hydrocodone/acetaminophen, morphine immediate-release (IR), hydromorphone IR, morphine extended-release (ER) and fentanyl transdermal -AND-
- Patient has documented clinically significant pain relief with trial of, but intolerance to oxycodone (IR) and oxycodone extended-release tablets<sup>†</sup>
- Prescriber is an Oncologist, Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program or a Pain Management Specialist.
- Since new enrollment in Kaiser Permanente, patient has had appointment in the prior 3 months with prescriber and pain management was discussed.

**Continued use criteria (3 months after initiation and for patients stable on the medication):** Non-formulary oxycodone extended-release (Xtampza ER) will continue to be covered on the prescription drug benefit for 3 months when the following criteria are met:

- Patient has failed an adequate trial<sup>^</sup> of or has an allergy or intolerance or contraindication\* to hydrocodone/acetaminophen, morphine immediate-release (IR), hydromorphone IR, morphine extended-release (ER) and fentanyl transdermal -AND-
- Patient has documented clinically significant pain relief with trial of, but intolerance to oxycodone (IR) and oxycodone extended-release tablets<sup>†</sup>
- Prescriber is an Oncologist, Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program or a Pain Management Specialist
- Patient has had an appointment with prescriber within prior 3 months and pain management was discussed.